Abstract:
Briefly, in one aspect, the present invention relates to processes for producing a stabilized Mn4+ doped phosphor in solid form and a composition containing such doped phosphor. Such process may include combining a) a solution comprising at least one substance selected from the group consisting of: K2HPO4, an aluminum phosphate, oxalic acid, phosphoric acid, a surfactant, a chelating agent, or a combination thereof, with b) a Mn4+ doped phosphor of formula I in solid form, where formula I may be: Ax [MFy]:Mn4+. The process can further include isolating the stabilized Mn4+ doped phosphor in solid form. In formula I, A may be Li, Na, K, Rb, Cs, or a combination thereof. In formula I, M may be Si, Ge, Sn, Ti, Zr, Al, Ga, In, Sc, Y, La, Nb, Ta, Bi, Gd, or a combination thereof. In formula I, x is the absolute value of the charge of the [MFy] ion and y is 5, 6 or 7.
Abstract:
Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprising a nanoparticulate transition metal oxide covalently functionalized with a silane-functionalized non-targeting zwitterionic moiety.
Abstract:
Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprising a nanoparticulate transition metal oxide covalently functionalized with a silane-functionalized non-targeting zwitterionic moiety.
Abstract:
A phosphor composition includes an activated uranium-based phosphor having formula I or II. The phosphor is doped with Eu3+ [Ba1−a−bSraCab]x[Mg,Zn]y(UO2)z([P,V]O4)2(x+y+z)/3 (I) [Ba1−a−bSraCab]p(UO2)q[P,V]rO(2p+2q+5r)/2 (II) where 0≤a≤1, 0≤b≤1, 0.75≤x≤1.25, 0.75≤y≤1.25, 0.75≤z≤1.25, 2.5≤p≤3.5, 1.75≤q≤2.25, and 3.5≤r≤4.5 and formula II excludes the combination where a is 0, b is 0, p is 3.5, q is 1.75, and r is 3.5. Phosphor compositions further including formula VI or other luminescent materials, such as quantum dots, devices and displays are also provided.
where 0≤a≤1, 0≤b≤1, 0.75≤x≤1.25, 0.75≤y≤1.25, 0.75≤z≤1.25, 2.5≤p≤3.5, 1.75≤q≤2.25, and 3.5≤r≤4.5 and formula II excludes the combination where a is 0, b is 0, p is 3.5, q is 1.75, and r is 3.5. Phosphor compositions further including formula VI or other luminescent materials, such as quantum dots, devices and displays are also provided.
Abstract:
Green-emitting phosphors are useful in devices including an LED light source radiationally coupled and/or optically coupled to the phosphors, which are selected from
[Ba1−a−bSraCab]x[Mg,Zn]y(UO2)z([P,V]O4)2(x+y+z)/3, where 0≤a≤1, 0≤b≤1, 0.75≤x≤1.25, 0.75≤y≤1.25, 0.75≤z≤1.25; and [Ba,Sr,Ca,Mg,Zn]p(UO2)q[P,V]rO(2p+2q+5r)/2, where 2.5≤p≤3.5, 1.75≤q≤2.25, 3.5≤r≤4.5.
Abstract:
Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprising a nanoparticulate transition metal oxide covalently functionalized with a silane-functionalized non-targeting zwitterionic moiety.
Abstract:
The present disclosure relates to a composition of albumin microbubbles to which are bound one or more moieties that exhibit a binding preference for the albumin microbubbles relative to free, native HSA. Production of the albumin microbubble composition and use of the albumin microbubble composition in ultrasound mediated delivery of therapeutic or diagnostic agents is also discussed.